13 November 2026

ASX Announcement

Investor webinar

MELBOURNE Australia, 13 November 2026: Australian antiviral drug development and biodefence company, Island Pharmaceuticals Ltd (**ASX: ILA**; **Island** or **the Company**) is pleased to invite shareholders and investors to attend an investor webinar on **Tuesday, 17 November 2026 at 11:00am AEDT (8:00am AWST)**.

The webinar will be hosted by Island's CEO and Managing Director, Dr David Foster, and Chairman, Mr Jason Carroll, who will provide an update on recent progress across the Company's Galidesivir development program, including preparations for its upcoming Marburg dose optimisation study and broader clinical and regulatory development activities.

Management will discuss the objectives and anticipated timelines of the upcoming study, which remains on track to commence dosing in early December CY2026, as well as its role in informing the Company's planned pivotal confirmatory efficacy study under the US Food and Drug Administration's (FDA) Animal Rule pathway.

The webinar will also provide shareholders with an overview of Island's broader development strategy, recent achievements and key milestones anticipated over the coming months.

An interactive Q&A session will follow the presentation, providing shareholders with an opportunity to ask questions directly of management.

Details:

- Date: Tuesday, 17 November 2026
- Time: 11:00am AEDT (8:00am AWST)
- Link: https://us02web.zoom.us/webinar/register/WN_FFlx2_sXSdmIJd5GWWTWdw

A recording of the webinar will be made available following the event.

- Ends -

Approved for release to the ASX by:
The Board of Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.